| 引用本文: | 吴庆荣,张丽华,张宇,杨雨婷,张浩,龚享文,宋晓兵.药物重整对尘肺合并慢性阻塞性肺疾病患者慢病管理的效果评价[J].中国现代应用药学,2026,43(19):99-105. |
| wuqingrong,zhanglihua,zhangyu,yangyuting,zhanghao,gongxiangwen,songxiaobing.Effect Evaluation of Medication Reconciliation in Chronic Disease Management for Elderly Patients with Pneumoconiosis-Complicated Chronic Obstructive Pulmonary Disease[J].Chin J Mod Appl Pharm(中国现代应用药学),2026,43(19):99-105. |
|
| |
|
|
| 本文已被:浏览 19次 下载 9次 |
 码上扫一扫! |
| 药物重整对尘肺合并慢性阻塞性肺疾病患者慢病管理的效果评价 |
|
吴庆荣,张丽华,张宇,杨雨婷,张浩,龚享文,宋晓兵
|
|
赣州市第五人民医院
|
|
| 摘要: |
| 目的:探讨以临床药师为主导的药物重整服务对尘肺合并慢性阻塞性肺病患者慢病管理的效果。方法:采用前瞻性随机对照研究设计,选取200例尘肺合并慢性阻塞性肺病患者随机分为干预组(100例)和对照组(100例)。所有入组患者均接受常规检查和治疗,干预组在此基础上增加由临床药师实施提供的药物重整服务。比较两组患者出院后1个月及3个月时的肺功能指标(FEV1%和6MWD)、临床症状评分(CAT和mMRC评分)、用药依从性评分及依从性差的患者比例、出院90天内再入院率以及住院期间相关经济性指标。结果:随访期间干预组和对照组脱落率分别为5例(5.00%)和8例(8.00%)。干预组中有51例(51.00%)患者存在至少1个用药偏差。出院后3个月,干预组的FEV1%和6MWD水平显著优于入院时(P<0.05),且均明显高于对照组(P<0.05)。干预组出院后1个月及3个月的CAT和mMRC评分较入院时显著性下降(P<0.05),且均明显低于同期对照组(P<0.05)。干预组随访期内再入院率和药物不良发生率显著低于对照组(P<0.05)。干预组出院后1个月及3个月的用药依从性评分较入院时和同期对照组均有显著性提高(P<0.05),且依从性差的患者比例下降幅度明显低于对照组(P<0.05)。此外,两组患者治疗期间的总住院费用、药品费用以及药占比等指标差异具有统计学意义(P<0.05)。结论:临床药师主导的药物重整服务可有效减少尘肺病合并慢性阻塞性肺病患者的用药偏差,显著改善其肺功能和症状控制,提升用药依从性,降低再入院与ADR发生风险,为保障患者用药安全与减轻医疗经济负担提供了有效策略。 |
| 关键词: 药物重整 尘肺 慢性阻塞性肺病 慢病管理 用药依从性 |
| DOI: |
| 分类号: |
| 基金项目:赣州市卫生健康委员会市级科研计划项目(NO:GZWJW202402245) |
|
| Effect Evaluation of Medication Reconciliation in Chronic Disease Management for Elderly Patients with Pneumoconiosis-Complicated Chronic Obstructive Pulmonary Disease |
|
wuqingrong1,2,3, zhanglihua, zhangyu, yangyuting, zhanghao, gongxiangwen, songxiaobing1,2,3
|
|
1.The Fifth People'2.'3.s Hospital of Ganzhou City
|
| Abstract: |
| Objective: To evaluate the effectiveness of a clinical pharmacist-led medication reconciliation (MR) service in the chronic disease management of patients with pneumoconiosis and chronic obstructive pulmonary disease (COPD). Methods: A prospective randomized controlled trial was conducted. Two hundred patients with pneumoconiosis and COPD were randomly assigned to either an intervention group (n=100) or a control group (n=100). All enrolled patients received conventional examination and treatment, while the intervention group additionally received a structured MR service provided by clinical pharmacists. Parameters compared between the two groups at 1 and 3 months post-discharge included lung function indicators (FEV1% and 6MWD), clinical symptom scores (CAT and mMRC), medication adherence scores, the proportion of patients with poor adherence, the 90-day readmission rate, and relevant economic indicators during hospitalization. Results: During follow-up, 5 (5.00%) and 8 (8.00%) patients were lost in the intervention and control groups, respectively. In the intervention group, 51 patients (51.00%) had at least one medication discrepancy. At 3 months post-discharge, FEV1% and 6MWD in the intervention group were significantly improved compared to baseline (P<0.05) and were notably higher than those in the control group (P<0.05). CAT and mMRC scores in the intervention group were significantly reduced at both 1 and 3 months post-discharge compared to admission levels (P<0.05) and were significantly lower than those in the control group at the corresponding time points (P<0.05). The readmission rate and incidence of adverse drug reactions (ADRs) were significantly lower in the intervention group than in the control group (P<0.05). Medication adherence scores in the intervention group were significantly higher at both follow-ups compared to both their own baseline and the concurrent control group (P<0.05), and the proportion of patients with poor adherence decreased more markedly than in the control group (P<0.05). Furthermore, statistically significant differences (P<0.05) were observed between the two groups in total hospitalization costs, medication costs, and the drug-to-cost ratio. Conclusion: The clinical pharmacist-led MR service effectively reduced medication discrepancies, significantly improved lung function and symptom control, enhanced medication adherence, and lowered the risks of readmission and ADRs in patients with pneumoconiosis and COPD. It provides an effective strategy for ensuring medication safety and alleviating the economic burden on the healthcare system. |
| Key words: Medication reconciliation Pneumoconiosis Chronic obstructive pulmonary disease Chronic disease management Medication compliance |
|
|
|
|